Jason Marchi
Nurse Practitioner · Boston, MANPI 1578938379
Payments from drug & device makers
Across 76 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$198
- AbbVie$178
- Lilly USA, LLC$120
- AstraZeneca$115
- Novo Nordisk$113
- Otsuka America Pharmaceutical, Inc.$110
- plus $731 from 13 others
What the payments were for
- Food & beverage$1,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $198 |
| AbbVie | 9 | $178 |
| Lilly USA, LLC | 5 | $120 |
| AstraZeneca | 6 | $115 |
| Novo Nordisk | 5 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| Shield Therapeutics Inc | 5 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $95 |
| GSK | 5 | $90 |
| Abbott | 4 | $90 |
| Exact Sciences | 3 | $78 |
| Amgen | 3 | $66 |
| Bayer | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Lucid Diagnostics Inc. | 2 | $36 |
| Seqirus USA Inc | 1 | $24 |
| Astellas Pharma US Inc | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
How this compares
$1,566 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 103 | $65,072 |
| JanuviaSitagliptin Phosphate | 38 | $36,621 |
| JardianceEmpagliflozin | 41 | $34,550 |
| EliquisApixaban | 34 | $24,286 |
| OzempicSemaglutide | 25 | $23,796 |
| OxycontinOxycodone Hcl | 27 | $13,258 |
| TradjentaLinagliptin | 13 | $12,063 |
| LinzessLinaclotide | 18 | $11,208 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,670 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,528 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,823 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 145 | $4,142 |
| Omeprazole | 166 | $2,615 |
| Atorvastatin Calcium | 197 | $2,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $115 | $71,895115 claims |
| PfizerEliquis | $198 | $24,28634 claims |
| Novo NordiskOzempic | $113 | $23,79625 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $90 | $21,34741 claims |
| AbbVieLinzess, Synthroid | $178 | $11,83433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Boston
- Alison McManusBoston$346K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Miu Lai NgBoston$33K
- Lauren BurkeBoston$26K
- Ashley HilmesBoston$24K
- Kristina SkarbinskiBoston$24K
- Hilary UgrasBoston$19K
- Colleen TigheBoston$17K
- Stephanie McDonaldBoston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.